These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21484597)

  • 1. Angelman syndrome: advancing the research frontier of neurodevelopmental disorders.
    Philpot BD; Thompson CE; Franco L; Williams CA
    J Neurodev Disord; 2011 Mar; 3(1):50-6. PubMed ID: 21484597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angelman syndrome at the synapse: meeting report of the Angelman Syndrome Foundation's 2009 scientific symposium.
    Williams C; Franco L
    J Child Neurol; 2010 Feb; 25(2):254-61. PubMed ID: 20101047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Autism and Angelman Syndrome Protein Ube3A/E6AP: The Gene, E3 Ligase Ubiquitination Targets and Neurobiological Functions.
    Khatri N; Man HY
    Front Mol Neurosci; 2019; 12():109. PubMed ID: 31114479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity-Dependent Arc Expression and Homeostatic Synaptic Plasticity Are Altered in Neurons from a Mouse Model of Angelman Syndrome.
    Pastuzyn ED; Shepherd JD
    Front Mol Neurosci; 2017; 10():234. PubMed ID: 28804447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interlinked destinies: How ubiquitin-proteasome and autophagy systems underpin neurocognitive outcomes.
    Yang X; Duckhorn J; Marshall J; Huang YA
    Exp Neurol; 2024 Sep; 379():114869. PubMed ID: 38901755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of UBE3A Protein in CSF and Extracellular Space of the Hippocampus Suggest a Potential Novel Function in Synaptic Plasticity.
    Dodge A; Willman J; Willman M; Nenninger AW; Morrill NK; Lamens K; Greene H; Weeber EJ; Nash KR
    Autism Res; 2021 Apr; 14(4):645-655. PubMed ID: 33474832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards an understanding of Angelman syndrome in mice studies.
    Yang X
    J Neurosci Res; 2020 Jun; 98(6):1162-1173. PubMed ID: 31867793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UBE3A and Its Link With Autism.
    Vatsa N; Jana NR
    Front Mol Neurosci; 2018; 11():448. PubMed ID: 30568575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.
    Meng L; Ward AJ; Chun S; Bennett CF; Beaudet AL; Rigo F
    Nature; 2015 Feb; 518(7539):409-12. PubMed ID: 25470045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc.
    Greer PL; Hanayama R; Bloodgood BL; Mardinly AR; Lipton DM; Flavell SW; Kim TK; Griffith EC; Waldon Z; Maehr R; Ploegh HL; Chowdhury S; Worley PF; Steen J; Greenberg ME
    Cell; 2010 Mar; 140(5):704-16. PubMed ID: 20211139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From UBE3A to Angelman syndrome: a substrate perspective.
    Sell GL; Margolis SS
    Front Neurosci; 2015; 9():322. PubMed ID: 26441497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypersociability in the Angelman syndrome mouse model.
    Stoppel DC; Anderson MP
    Exp Neurol; 2017 Jul; 293():137-143. PubMed ID: 28411125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ube3a, the E3 ubiquitin ligase causing Angelman syndrome and linked to autism, regulates protein homeostasis through the proteasomal shuttle Rpn10.
    Lee SY; Ramirez J; Franco M; Lectez B; Gonzalez M; Barrio R; Mayor U
    Cell Mol Life Sci; 2014 Jul; 71(14):2747-58. PubMed ID: 24292889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential therapeutic approaches for Angelman syndrome.
    Bi X; Sun J; Ji AX; Baudry M
    Expert Opin Ther Targets; 2016; 20(5):601-13. PubMed ID: 26558806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative proteomics reveals neuronal ubiquitination of Rngo/Ddi1 and several proteasomal subunits by Ube3a, accounting for the complexity of Angelman syndrome.
    Ramirez J; Lectez B; Osinalde N; Sivá M; Elu N; Aloria K; Procházková M; Perez C; Martínez-Hernández J; Barrio R; Šašková KG; Arizmendi JM; Mayor U
    Hum Mol Genet; 2018 Jun; 27(11):1955-1971. PubMed ID: 29788202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial Superoxide Contributes to Hippocampal Synaptic Dysfunction and Memory Deficits in Angelman Syndrome Model Mice.
    Santini E; Turner KL; Ramaraj AB; Murphy MP; Klann E; Kaphzan H
    J Neurosci; 2015 Dec; 35(49):16213-20. PubMed ID: 26658871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JNK signaling activation in the Ube3a maternal deficient mouse model: its specific inhibition prevents post-synaptic protein-enriched fraction alterations and cognitive deficits in Angelman Syndrome model.
    Musi CA; Agrò G; Buccarello L; Camuso S; Borsello T
    Neurobiol Dis; 2020 Jul; 140():104812. PubMed ID: 32087286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UBE3A: An E3 Ubiquitin Ligase With Genome-Wide Impact in Neurodevelopmental Disease.
    Lopez SJ; Segal DJ; LaSalle JM
    Front Mol Neurosci; 2018; 11():476. PubMed ID: 30686997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcellular organization of UBE3A in human cerebral cortex.
    Burette AC; Judson MC; Li AN; Chang EF; Seeley WW; Philpot BD; Weinberg RJ
    Mol Autism; 2018; 9():54. PubMed ID: 30364390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angelman Syndrome: From Mouse Models to Therapy.
    Rotaru DC; Mientjes EJ; Elgersma Y
    Neuroscience; 2020 Oct; 445():172-189. PubMed ID: 32088294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.